(Q33343994)

26 July 2017

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

acute myeloid leukemia

1 reference

inferred from title

author

Frederick R. Appelbaum

15

object named as

F R Appelbaum

1 reference

26 July 2017

1

R A Larson

1 reference

26 July 2017

5

E A Stadtmauer

1 reference

26 July 2017

M Boogaerts

2

1 reference

26 July 2017

E Estey

3

1 reference

26 July 2017

C Karanes

4

1 reference

26 July 2017

E L Sievers

6

1 reference

26 July 2017

P Mineur

7

1 reference

26 July 2017

J M Bennett

8

1 reference

26 July 2017

M S Berger

9

1 reference

26 July 2017

C B Eten

10

1 reference

26 July 2017

M Munteanu

11

1 reference

26 July 2017

M R Loken

12

1 reference

26 July 2017

J J M Van Dongen

13

1 reference

26 July 2017

I D Bernstein

14

1 reference

26 July 2017

Mylotarg Study Group

16

1 reference

26 July 2017

language of work or name

1 reference

1 September 2002

1 reference

26 July 2017

1 reference

26 July 2017

16

1 reference

26 July 2017

1627-1636

1 reference

26 July 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402677

26 July 2017

0 references

cites work

Treatment of acute myelogenous leukemia in older adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Acute myeloid leukemia in the elderly: 'per aspera ad astra'?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Results of Therapy for Acute Myeloid Leukemia in First Relapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Reinduction chemotherapy for acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Management of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

An effective age-unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-cont

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402677

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402677

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference